Silo Pharma Q2 FY26 net loss narrows 30.8% to $832,829

• Silo Pharma posted a net loss of USD 832,829 in the quarter ended June 30, narrowing 30.8% from a year earlier.
• Revenue was nil, versus USD 18,025 a year earlier, as it stopped recognizing license and sublicense fee revenue after April 1.
• Operating loss narrowed 25.6% to USD 928,949 as operating expenses fell 26.6% to USD 928,949.
• Research and development expense dropped 58.4% to USD 298,418 on lower costs tied to investigator-sponsored studies and other projects.
• Liquidity totaled USD 3.28 million in cash and USD 1.95 million in short-term investments at June 30; July 9 private placement netted USD 3.53 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089085), on August 13, 2026, and is solely responsible for the information contained therein.